ATH: ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder

ALTERITY THERAPEUTICS LIMITED

• Alterity Therapeutics has initiated a second Phase 2 clinical trial of ATH434 in patients with Multiple System Atrophy (MSA).
• The trial will focus on measuring the efficacy of ATH434 on biomarkers and assessing clinical measures in individuals with more advanced MSA.
• Preliminary data from this trial is expected before the results of the ongoing randomized Phase 2 trial are available.

2023-05-30 13:32:00

ATH: US patent grant and license agreement

ALTERITY THERAPEUTICS LIMITED

• Alterity Therapeutics granted composition of matter patent for over 100 compounds targeting neurodegenerative diseases including Alzheimer's.
• Exclusive worldwide license for AH and PBT2 granted to Professor Colin Masters for evaluation in Alzheimer's and related diseases.
• Alterity is entitled to future royalties of net sales from the assets.

2023-03-14 10:42:00

ATH: First Patient Enrolled in Europe in Phase II Clinical trial

ALTERITY THERAPEUTICS LIMITED

• Alterity Therapeutics has initiated a Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and debilitating Parkinsonian disorder.
• The trial will evaluate the effect of ATH434 treatment on neuro imaging and protein biomarkers, as well as safety and pharmacokinetics.
• Around 60 adults will receive one of two dose levels of ATH434 or placebo over a 12-month period.

2023-03-08 09:19:00

ATH: Regulatory approval for Phase II trial in France and Austria

ALTERITY THERAPEUTICS LIMITED

• Alterity Therapeutics has been granted authorization to conduct a Phase 2 clinical trial for ATH434 in Multiple System Atrophy (MSA).
• The regulatory approvals in France and Austria will allow Alterity to expand its footprint in Europe.
• Alterity is focused on providing access to the Phase 2 clinical trial for individuals living with MSA.

2023-02-16 12:30:00

ATH: ATH434 Clinical Trial Launched in Italy

ALTERITY THERAPEUTICS LIMITED

• Alterity Therapeutics has launched a Phase 2 clinical trial of ATH434 for the treatment of individuals with Multiple System Atrophy in Italy.
• Recruitment is ongoing in Europe, Asia-Pacific, and the U.S. for the study of rapidly progressive Parkinsonian Disorder.
• This expands access to ATH434 to individuals living with MSA.

2023-01-25 09:50:00

ATH: ATH434 Clinical Trial Launched In The US

ALTERITY THERAPEUTICS LIMITED

1. Alterity Therapeutics has launched a Phase 2 clinical trial of ATH434 for the treatment of individuals with Multiple System Atrophy (MSA).
2. "The opening of enrol lment in the U.S. is a major milestone for this trial and we are now actively recruiting patients in three regions: Europe, Asia-Pacific, and the U.S."
3. Vanderbilt University Medical Center in Nashville, Tennessee is the first U.S. trial site.

2023-01-09 11:40:00

ATH: New US patent for compounds to treat neurodegeneration

ALTERITY THERAPEUTICS LIMITED

1. Patent covers more than 100 novel compounds targeting neurodegenerative diseases including Parkinson’s and Alzheimer’s.
2. Provides Alterity with 20 years of exclusivity.
3. Expands its intellectual property estate for treating major neurodegenerative diseases.

2022-12-29 11:56:00